written on 07.03.2014
pt:
Tags:
,

Novartis sees start of $2B dermatology opportunity with new EU Xolair approval

TAGS: ,

On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives–the first such product cleared there for patients who don't respond to antihistamines alone.

Latest Report